Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Labcorp Q3 revenue beats on organic growth, operating efficiencies 

By Reuters News


Overview

  • Global lab services provider's Q3 revenue rose 6.9% yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 rose 14.5% yr/yr

  • Company raised full-year 2026 revenue growth and adjusted EPS guidance


Outlook

  • Labcorp raises 2026 revenue growth outlook to 5.9%-6.7% and adj EPS to $18.30-$18.70

  • Company expects 2026 Biopharma Laboratory Services revenue growth of 7.4%-8.4%

  • Labcorp sees 2026 Diagnostics Laboratories revenue growth of 5.5%-6.2%


Result Drivers

  • ORGANIC GROWTH & OPERATING EFFICIENCIES - Co attributed higher adjusted operating income and margin to organic growth and operating efficiencies

  • ACQUISITIONS - Co said recent acquisitions are expected to contribute to adjusted EPS and long-term growth

  • SPECIALTY TESTING EXPANSION - Co launched new specialty tests and expanded access through acquisitions


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$3.81 bln

$3.76 bln (12 Analysts)

Q3 Adj EPS from Cont Ops

$4.78


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Labcorp Holdings Inc. is $355.00, about 7.2% above its October 27 closing price of $331.17

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Oct 27 - Healthcare data firm IQVIA Q3 revenue beats on strong bookings

  • Oct 27 - Centene Q3 revenue tops estimates on Medicare growth

  • Oct 27 - Ensign Group Q3 adjusted EPS beats estimates, revenue up on higher occupancy rates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.